Antimicrobial resistance biotech secures $37M with ex-CureVac CEO Franz-Werner Haas at the helm
Three months into his role at the helm of GSK’s bacterial infection spinout LimmaTech, CureVac veteran Franz-Werner Haas is focused on scaling the company. And now he has an extra $37 million to work with.
LimmaTech announced the financing round early Monday morning, led by Adjuvant Capital, AXA IM Alts and the Novo Holdings REPAIR Impact Fund. LimmaTech was founded in 2015, and closing a Series A seven years into a company’s life is “a bit abnormal,” Haas conceded. But the money will come in handy as the biotech looks to chart its own path outside a research collaboration with GSK.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.